

Keith W Pratz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3010321/publications.pdf>

Version: 2024-02-01

112
papers

8,375
citations

101535

36
h-index

48312

88
g-index

113
all docs

113
docs citations

113
times ranked

8301
citing authors

#	ARTICLE	IF	CITATIONS
1	Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Japanese Journal of Clinical Oncology, 2022, 52, 29-38.	1.3	10
2	Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia. Cancer Journal (Sudbury, Mass), 2022, 28, 14-20.	2.0	3
3	Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. Journal of Clinical Oncology, 2022, 40, 855-865.	1.6	86
4	Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer Journal, 2022, 12, 71.	6.2	12
5	Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2022, 97, .	4.1	5
6	Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective. Pharmacoeconomics, 2022, 40, 777-790.	3.3	6
7	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood, 2021, 137, 1792-1803.	1.4	123
8	Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. American Journal of Hematology, 2021, 96, 208-217.	4.1	95
9	CDK2-Mediated Upregulation of TNF α as a Mechanism of Selective Cytotoxicity in Acute Leukemia. Cancer Research, 2021, 81, 2666-2678.	0.9	5
10	Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis. Blood Advances, 2021, 5, 2285-2293.	5.2	11
11	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory) Tj ETQq1 1 0.784314 rgBT /Overbo	1.4	3
12	Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective. Blood, 2021, 138, 112-112.	1.4	3
13	A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma. Blood, 2021, 138, 4401-4401.	1.4	5
14	Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax Combined with Hypomethylating Agents. Blood, 2021, 138, 224-224.	1.4	16
15	Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitidine for Initial Therapy in Adult Acute Myeloid Leukemia. Blood, 2021, 138, 795-795.	1.4	7
16	CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL. Blood, 2021, 138, 469-469.	1.4	7
17	A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 300-306.	2.0	36
18	Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. Leukemia, 2020, 34, 1563-1576.	7.2	17

#	ARTICLE	IF	CITATIONS
19	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine, 2020, 383, 617-629.	27.0	1,407
20	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV, 2020, 7, e602-e610.	4.7	11
21	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematology, 2020, 7, e601-e612.	4.6	56
22	Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. Blood Advances, 2020, 4, 5078-5088.	5.2	23
23	Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation. Leukemia and Lymphoma, 2020, 61, 2200-2207.	1.3	8
24	Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1385-1415.	4.9	147
25	Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide. American Journal of Clinical Pathology, 2019, 152, 675-685.	0.7	2
26	Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction. Leukemia Research, 2019, 83, 106174.	0.8	8
27	BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated miR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies. Clinical Cancer Research, 2019, 25, 2513-2522.	7.0	11
28	Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood, 2019, 133, 7-17.	1.4	1,254
29	A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. American Journal of Hematology, 2019, 94, 111-117.	4.1	21
30	Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies. Blood, 2019, 134, 264-264.	1.4	21
31	Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study. Blood, 2019, 134, 3910-3910.	1.4	34
32	Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2019, 134, 3897-3897.	1.4	5
33	Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML). Blood, 2019, 134, 1309-1309.	1.4	9
34	Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study. Blood, 2019, 134, 115-115.	1.4	19
35	Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 721-749.	4.9	314
36	Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis. Blood, 2019, 134, 3841-3841.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 2209-2209.	1.4	4
38	Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. <i>Lancet Oncology</i> , 2018, 19, 216-228.	10.7	551
39	Acute myeloid leukemia in the elderly: therapeutic options and choice. <i>Leukemia and Lymphoma</i> , 2018, 59, 274-287.	1.3	59
40	Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 213-221.	4.1	81
41	Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions. <i>Blood</i> , 2018, 132, 560-560.	1.4	51
42	Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 564-564.	1.4	41
43	Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial. <i>Blood</i> , 2018, 132, 437-437.	1.4	4
44	Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy. <i>Blood</i> , 2018, 132, 285-285.	1.4	29
45	FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years. <i>Blood</i> , 2018, 132, 3995-3995.	1.4	3
46	Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS). <i>Blood</i> , 2018, 132, 335-335.	1.4	0
47	Topoisomerase I-DNA Covalent Complexes in Myeloid Malignancies: A Potential Biomarker for Topoisomerase I Inhibitor Sensitivity. <i>Blood</i> , 2018, 132, 5146-5146.	1.4	1
48	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. <i>Haematologica</i> , 2017, 102, 391-400.	3.5	152
49	Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1688-1700.	2.4	7
50	A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete Remission. <i>Journal of Palliative Medicine</i> , 2017, 20, 1267-1273.	1.1	8
51	How I treat FLT3-mutated AML. <i>Blood</i> , 2017, 129, 565-571.	1.4	66
52	Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies. <i>Cancer Research</i> , 2017, 77, 5554-5563.	0.9	36
53	Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 926-957.	4.9	451
54	Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature. <i>Leukemia Research</i> , 2017, 61, 25-32.	0.8	12

#	ARTICLE	IF	CITATIONS
55	Exposureâ€Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies. <i>Clinical Cancer Research</i> , 2017, 23, 6421-6429.	7.0	4
56	Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 959-966.	4.9	6
57	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 697-706.	7.0	56
58	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 899-907.	7.0	37
59	Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2017, 130, 722-722.	1.4	84
60	Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial. <i>Blood</i> , 2017, 130, 726-726.	1.4	20
61	Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. <i>Clinical Cancer Research</i> , 2016, 22, 3894-3902.	7.0	23
62	Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies. <i>Leukemia Research</i> , 2016, 49, 90-97.	0.8	11
63	4EBP1/c-MYC/PUMA and NF- κ B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. <i>Blood</i> , 2016, 127, 2711-2722.	1.4	49
64	Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia. <i>Haematologica</i> , 2016, 101, e228-e231.	3.5	47
65	a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML). <i>Blood</i> , 2016, 128, 2834-2834.	1.4	13
66	Structural Chromosomal Changes Are Common Manifestation of FLT3 ITD Relapse and Presence of Chromosomal Progression Is Independent of Normal Karyotype at Diagnosis. <i>Blood</i> , 2016, 128, 2868-2868.	1.4	3
67	Signaling Adaptation to TKI Treatment Reactivates ERK Signaling in FLT3/ITD Leukemia. <i>Blood</i> , 2016, 128, 33-33.	1.4	3
68	Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age \geq 60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial. <i>Blood</i> , 2016, 128, 339-339.	1.4	7
69	Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS). <i>Blood</i> , 2016, 128, 2820-2820.	1.4	0
70	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. <i>Blood</i> , 2015, 125, 3024-3031.	1.4	259
71	Real-Life Experience of a Brief Arsenic Trioxide-Based Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia: Favorable Outcomes With Limited Anthracycline Exposure and Shorter Consolidation Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 292-297.	0.4	9
72	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. <i>Journal of Clinical Oncology</i> , 2015, 33, 3152-3161.	1.6	215

#	ARTICLE	IF	CITATIONS
73	A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML. Molecular Diagnosis and Therapy, 2015, 19, 409-417.	3.8	8
74	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias. Blood, 2015, 126, 1361-1361.	1.4	2
75	North American Leukemia, Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy, and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906). Blood, 2015, 126, 217-217.	1.4	28
76	Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation. Blood, 2015, 126, 3164-3164.	1.4	24
77	A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naïve Patients with Acute Myelogenous Leukemia Who Are ≥65 Years and Not Eligible for Standard Induction Therapy. Blood, 2015, 126, 327-327.	1.4	37
78	Liberal Vs. Restrictive Transfusion Thresholds in Leukemia Patients: A Feasibility Pilot Study. Blood, 2015, 126, 771-771.	1.4	2
79	Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant. American Journal of Hematology, 2014, 89, 936-938.	4.1	35
80	Will FLT3 inhibitors fulfill their promise in acute myeloid leukemia?. Current Opinion in Hematology, 2014, 21, 72-78.	2.5	25
81	Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro. Leukemia Research, 2014, 38, 411-417.	0.8	7
82	HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 314-318.	2.0	103
83	Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1989-1995.	2.0	31
84	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood, 2014, 124, 3817-3827.	1.4	165
85	A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. Haematologica, 2014, 99, 672-678.	3.5	48
86	Epigenetic Silencing of BRCA1 Is Linked to Homologous Recombination Repair Defects and Elevated Mir-155 Expression in Myeloid Neoplasms. Blood, 2014, 124, 3525-3525.	1.4	1
87	A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906. Blood, 2014, 124, 3742-3742.	1.4	5
88	Results Of a Phase 1 Study Of Quizartinib (AC220, ASP2689) In Combination With Induction and Consolidation Chemotherapy In Younger Patients With Newly Diagnosed Acute Myeloid Leukemia. Blood, 2013, 122, 623-623.	1.4	14
89	A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 1427-1427.	1.4	0
90	Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias. Clinical Cancer Research, 2012, 18, 6723-6731.	7.0	100

#	ARTICLE	IF	CITATIONS
91	Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. <i>Haematologica</i> , 2012, 97, 1736-1742.	3.5	65
92	Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients. <i>Investigational New Drugs</i> , 2012, 30, 2096-2102.	2.6	42
93	Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. <i>British Journal of Haematology</i> , 2012, 158, 198-207.	2.5	7
94	Tandem Duplication PCR (TD-PCR) Is a Novel Method of Detecting Minimal Residual Disease in FLT3/ITD AML and Is Highly Predictive of Relapse Risk Following Allogeneic Transplant.. <i>Blood</i> , 2012, 120, 2479-2479.	1.4	2
95	Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 1516-1516.	1.4	9
96	Phase I Dose-Escalation Study of SCH 900776 in Combination with Cytarabine (Ara-C) in Patients with Acute Leukemia. <i>Blood</i> , 2011, 118, 1531-1531.	1.4	2
97	Final Results From a Phase II Trial of Triapine® Plus Fludarabine for Adults with Aggressive Myeloproliferative Disorders. <i>Blood</i> , 2011, 118, 1755-1755.	1.4	3
98	Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined With Topotecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias,. <i>Blood</i> , 2011, 118, 3634-3634.	1.4	6
99	Genetic and Epigenetic Defects in DNA Repair Lead to Synthetic Lethality of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in Aggressive Myeloproliferative Disorders. <i>Blood</i> , 2011, 118, 400-400.	1.4	5
100	FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. <i>Blood</i> , 2010, 115, 1425-1432.	1.4	212
101	Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 3033-3038.	2.3	46
102	Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1856-1862.	1.6	347
103	Bench to Bedside Targeting of FLT3 in Acute Leukemia. <i>Current Drug Targets</i> , 2010, 11, 781-789.	2.1	33
104	Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined With Topotecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias. <i>Blood</i> , 2010, 116, 3276-3276.	1.4	0
105	Preliminary Clinical, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of the Safety Run In Part of a Phase II Trial of the Orally Available MEK-Inhibitor MSC1936369 In Patients with Advanced Hematological Malignancies. <i>Blood</i> , 2010, 116, 3296-3296.	1.4	0
106	A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. <i>Blood</i> , 2009, 113, 3938-3946.	1.4	159
107	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). <i>Blood</i> , 2009, 114, 2984-2992.	1.4	521
108	FLT3 Mutant to Wild Type Allelic Ratio and Clinical Status Are Predictive of Response to FLT3 Inhibitors in AML.. <i>Blood</i> , 2009, 114, 1716-1716.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Leukemia and Lymphoma, 2008, 49, 852-863.	1.3	44
110	Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3. Blood, 2008, 112, 2637-2637.	1.4	6
111	A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML. Blood, 2008, 112, 2967-2967.	1.4	11
112	Large Cell Carcinoma With Calcitonin and Vasoactive Intestinal Polypeptideâ€“Associated Verner-Morrison Syndrome. Mayo Clinic Proceedings, 2005, 80, 116-120.	3.0	15